Opendata, web and dolomites

RECOGNISED SIGNED

Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "RECOGNISED" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA 

Organization address
address: PASSEIG VALL D HEBRON 119-129 EDIFICIO DE RECERCA
city: BARCELONA
postcode: 8035
website: http://www.vhir.org/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 5˙998˙272 €
 EC max contribution 5˙998˙272 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA ES (BARCELONA) coordinator 950˙410.00
2    AIBILI ASSOCIACAO PARA INVESTIGACAO BIOMEDICA E INNOVACAO EM LUZ E IMAGEM PT (COIMBRA) participant 822˙760.00
3    THE QUEEN'S UNIVERSITY OF BELFAST UK (BELFAST) participant 763˙001.00
4    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 589˙000.00
5    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 450˙000.00
6    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 297˙207.00
7    SYDDANSK UNIVERSITET DK (ODENSE M) participant 250˙000.00
8    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) participant 250˙000.00
9    UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA IT (ROMA) participant 248˙250.00
10    UNIVERSIDAD DE CADIZ ES (CADIZ) participant 229˙672.00
11    INSTITUT CATALA DE LA SALUT ES (BARCELONA) participant 196˙021.00
12    AZIENDA OSPEDALIERO-UNIVERSITARIA MAGGIORE DELLA CARITA NOVARA IT (NOVARA) participant 183˙750.00
13    FUNDACIO ASSISTENCIAL DE MUTUA DE TERRASSA FUNDACIO PRIVADA CATALANA ES (TERRASSA) participant 180˙950.00
14    KLINICKI CENTAR CRNE GORE PODGORICA ME (PODGORICA) participant 127˙500.00
15    EATRIS ERIC NL (AMSTERDAM) participant 104˙000.00
16    GENESIS BIOMED ES (BARCELONA) participant 100˙875.00
17    ANAXOMICS BIOTECH SL ES (BARCELONA) participant 95˙000.00
18    JAVNA USTANOVA UNIVERZITET CRNE GORE PODGORICA ME (PODGORICA) participant 54˙875.00
19    ALZHEIMER EUROPE LU (LUXEMBOURG) participant 35˙000.00
20    FEDERATION INTERNATIONALE DU DIABETE REGION EUROPE AISBL BE (BRUXELLES) participant 35˙000.00
21    OXURION BE (LEUVEN) participant 35˙000.00

Map

 Project objective

In recent years there is mounting evidence that type 2 diabetes (T2D) is associated with cognitive impairment and dementia, which can be considered as a “new” long-term diabetic co-morbid complication with dramatic consequences for patients and their families and a significant impact for healthcare systems. At present there are no reported phenotypic indicators or reliable tests to identify T2D patients at risk of developing dementia. Since the retina is ontogenically a brain-derived tissue, we propose that the evaluation of retinal parameters related to either neurodegeneration or microvascular disease will be robust and valuable biomarkers to identify those T2D patients at higher risk of developing cognitive impairment and dementia. On this basis the overarching aims of the project are: 1) To investigate the common mechanisms involved in the pathogenesis of DR and cognitive impairment in the T2D. 2) To use the retina as a tool to identifying individuals with T2D at a higher risk of developing cognitive decline or dementia. Our multidisciplinary consortium (RECOGNISED) consist of top research leaders in the field belonging to 15 prestigious institutions as well as EATRIS, IDF-Europe and Alzheimer Europe and 3 SMEs. RECOGNISED will apply innovative approaches to identify the molecular mechanisms involved in the high prevalence of cognitive impairment and dementia in T2D population and will use this knowledge to characterize clinical phenotypes (personalized medicine) based on retinal functional and structural characteristics and serum biomarkers in order to stratify the risk and severity of cognitive decline. Previously collected data from registries, cohorts and biobanks will be appropriately exploited and robust new data will be generated that will guide clinical recommendations and open up new therapeutic strategies. Ultimately, RECOGNISED project will help to reduce the huge societal and economic burden associated with diabetes-related cognitive impairment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RECOGNISED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RECOGNISED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

ESPACE (2020)

Human Cell Atlas of the Pancreas

Read More  

BRAINTIME (2020)

Molecular atlas of the brain across the human lifespan

Read More  

SoNAR-Global (2019)

A Global Social Sciences Network for Infectious Threats and Antimicrobial Resistance

Read More